INTRAURETHRAL PHARMACOTHERAPY (MUSE) |
In January of 1997, the FDA in the USA approved an intraurethral delivery
system, MUSE, for the treatment of Erectile Dysfunction. This
involves delivery of a pellet of the drug, alprostadil, into the distal
penile urethra using a plastic applicator. The pellet is held in the
urethra for several minutes until it dissolves and is absorbed into the
erectile tissue producing an erection.
Success rates with this treatment are in the 30 to 50% range. Side
effects of urethral burning and pain occur in 7 to 10% of men.
While not nearly as popular as oral drug therapy, the intraurethral
route of administration of alprostadil is the preferred treatment
method in a small percentage of couples. |
|
|
